The Chicago Entrepreneur

Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

Previous post The Siren Song of Sustainability: The Theocratic Trifecta’s Third Leg!
Next post GM expects more than $5 billion impact from China restructuring, including plant closures